Sort
82,697 grants matching “vaccine development”
Modeling the ecology of tissue-resident T cells
$986,013Andrew Yates · Columbia University Health Sciences · U01 · FY2020 · AI
Virus-Host Interactions: Induction and Evasion of Host Innate Immunity
$985,972Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Therapeutics that target processivity complex proteins of pox and other viruses
$985,959Robert Paul Ricciardi · University Of Pennsylvania · U01 · FY2010 · AI
Center for Computational Mass-Spectrometry
$985,859Pavel A Pevzner · University Of California, San Diego · P41 · FY2008 · RR
CENTER FOR COMPUTATIONAL MASS-SPECTROMETRY
$985,859Pavel A Pevzner · University Of California, San Diego · P41 · FY2008 · RR
Colorado AMC REACH Hub
$985,828Richard C Duke · University Of Colorado Denver · U01 · FY2022 · HL
Host Immunity Against Bacteria
$985,803Ian Myles · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
GLOBAL HIV VACCINE ENTERPRISE
$985,801Alan Bernstein · Global Hiv Vaccine Enterprise · N01 · FY2009 · AI
Transcutaneous Immunization for an Anthrax Vaccine
$985,771Iomai Corporation · R44 · FY2005 · AI
Does repeated influenza vaccination constrain influenza immune responses and protection?
$985,423Sheena G Sullivan · University Of Melbourne · R01 · FY2020 · AI
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
$985,298Rajan P Adhikari · Integrated Biotherapeutics, Inc. · R42 · FY2020 · AI
Improving the Efficacy of Dendritic Cell Vaccines
$985,145Jacques F Banchereau · Baylor Research Institute · P01 · FY2008 · CA
Epitranscriptomic regulation in the mammalian nervous system
$985,026Guo-Li Ming · University Of Pennsylvania · R35 · FY2025 · NS
Molecular Biology of Oncogenic Papillomaviruses
$985,021Peter M Howley · Harvard Medical School · R35 · FY2019 · CA
SEQUENCING THE GENOME BURKHOLDERIA MALLEI
$984,990Institute For Genomic Research · U01 · FY2001 · AI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
$984,986Paul Guyre · Celdara Medical, Llc · R44 · FY2021 · AI
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
$984,934Christian Harding · Vaxnewmo, Llc · R44 · FY2022 · AI
Novel DNA Repair Inhibitors for Cancer Therapy
$984,900Peter M Glazer · Yale University · R35 · FY2022 · CA
Mechanisms of human papillomavirus entry
$984,892Daniel Dimaio · Yale University · R35 · FY2023 · CA
Mechanisms of human papillomavirus entry
$984,892Daniel Dimaio · Yale University · R35 · FY2022 · CA
Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk
$984,840Eva Harris · University Of California Berkeley · U01 · FY2021 · AI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
$984,686Mark Yondola · Calder Biosciences, Inc. · R44 · FY2022 · AG
Intrarectal Immunization for a Barrier to Mucosal HIV Infection
$984,626Marie-Claire Elisabeth Gauduin · Texas Biomedical Research Institute · R01 · FY2024 · AI
Core C: Viral vector core
$984,566Guang-Ping Gao · Scripps Florida · U19 · FY2021 · AI
Biology and Therapy of T Cell Depletion
$984,566Crystal L Mackall · Clinical Sciences · Z01 · FY2007 · CA